Repertoire Immune Medicines - Latest News and Information
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Technology Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Sunday recap

NewsDealsSocialBlogsVideosPodcasts
HomeRepertoire Immune Medicines
Repertoire Immune Medicines logo

Repertoire Immune Medicines

0 followers

About Repertoire Immune Medicines

Repertoire Immune Medicines is a clinical-stage biotechnology company focused on discovering and developing programmable immune medicines to prevent or treat cancer, autoimmune diseases, and infectious diseases. The company leverages insights from the adaptive immune system, including its DECODE platform and immune synapse interactions, to design therapies targeting the T cell repertoire. Headquartered in the United States, Repertoire aims to translate immune codes into transformative medicines that can reprogram immune responses in patients.

Recent News

Recent Deals

No recent deals for this company.

Key Team Members

John Delyani, PhD, MBA

Chief Business Officer

Torben Straight Nissen, PhD

Chief Executive Officer

Regina Sherwood

Vice President of Human Resources

Anthony Coyle, PhD

President, Research and Development

Suzanne Greco

Vice President, Finance

Key Facts

HQ Location

Cambridge, United States

Founded

2020

Employees

51 - 200

Status

Private

Website

https://repertoire.com